H.C. Wainwright Reaffirms Their Buy Rating on Cybin (CYBN)
In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Cybin, with a price target of $150.00. The company’s shares closed yesterday at $6.05.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Trucchio is a 5-star analyst with an average return of 15.2% and a 46.19% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as GH Research, Arrowhead Pharmaceuticals, and Oncolytics Biotech.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cybin with a $79.60 average price target.
The company has a one-year high of $13.88 and a one-year low of $4.81. Currently, Cybin has an average volume of 484.9K.
Read More on CYBN:
Disclaimer & DisclosureReport an Issue
- Cybin Inc. Strengthens U.S. Market Position with New SEC Filing
- Cybin Inc. Announces CEO Transition as of September 2, 2025
- Cybin’s Promising Clinical Advancements and Strategic Positioning Justify Buy Rating
- Psychedelic: Cybin completes enrollment in CYB004 Phase 2 study
- Cybin to Engage in TD Cowen’s Neuropsychiatry Summit
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.